Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

Completed · Phase 1/Phase 2

Conditions studied: Open-angle Glaucoma, Ocular Hypertension

In brief

To investigate the safety and efficacy of DE-112 in lowering intraocular pressure in subjects with primary open-angle glaucoma or ocular hypertension.

Key facts

Study ID

NCT01279083

Run by

Santen Inc.

People needed

147

Starts

2011-01-01

Expected to finish

2012-02-01

Last updated by the study team

2012-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provide signed, written informed consent
• 18 yeas of age and older
• Diagnosed with primary open-angle glaucoma or ocular hypertension
• Female subject of childbearing potential must utilize reliable contraceptive throughout the study and have a negative urine pregnancy test prior to enrollment into this study
• Meet specific Visit 2, Day 0 (Baseline)criteria at baseline

You may not qualify if…

• Females who are pregnant, nursing or planning a pregnancy
• Presence of any abnormality or significant illness that could be expected to interfere with the study.

Where it is running

• Study site — Austin, Texas, United States
• Study site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.